Emcure pharma Results Analysis-Q4FY26

Operating Revenue for Q4FY26 is Rs. 2,470 Crs., 16.7% growth YoY, Total Income is Rs. 2,474 Crs., 16.65% growth YoY, Gross Profit is Rs. 1,467 Crs., 19.81% growth YoY, EBITDA is Rs. 485 Crs., 24.5% growth YoY, EBITDA Margin is 19.66% improved by 123 Basis points YoY (EBITDA margins improved despite increased R&D investment, supported by higher gross profit margin), PBT Rs. 341 Crs. 30.92% growth YoY, PAT Rs. 244 Crs. 23.58% growth YoY. Robust International Markets performance (revenue up 25.7% YoY); contribution at 60%. On QoQ basis Op. Revenue is up by 4.49%, Total Income is up by 4.58%, Gross Profit is up by 4.68%, EBITDA is up by 5.51%,, PBT is up by 8.73% and PAT is also up by 5.35%. Strategic portfolio expansion : Partnership with Novo Nordisk for Poviztra, expansion of Sanofi partnership for oral anti-diabetic portfolio (Amaryl & Cetapin); Roche partnership for nephrology and transplant products Full consolidation of Zuventus through minority stake buyout Manx and Cutimed acquisitions in Europe and Canada, respectively.